Zeltiq Aesthetics
| Company type | Division |
|---|---|
| Industry | Medical devices |
| Founded | 2005 |
| Founder | Mitchell Levinson |
| Headquarters | Pleasanton, California , United States |
| Products | CoolSculpting Procedure (cryolipolysis devices) |
| Parent | AbbVie |
Zeltiq Aesthetics operates as a division of AbbVie, with its main office located in Pleasanton, California. The company focuses on manufacturing devices used in cryolipolysis treatments. Established in 2005 by entrepreneur Mitchell Levinson, Zeltiq secured $75 million in funding prior to its initial public offering in 2011. In 2017, Allergan acquired Zeltiq for $2.48 billion, and subsequently, AbbVie purchased Allergan in 2020 for $63 billion.
History
Initially named Juniper Medical, Inc., the company was founded by Mitch Levinson, who had formerly led Thermage, a business specializing in radio frequency devices for skin tightening. The firm adopted the name Zeltiq in 2007.
Zeltiq’s primary offering, the CoolSculpting Procedure, employs cryolipolysis technology to eliminate fat by cooling targeted tissue between two paddles to subfreezing temperatures for approximately 30 minutes. This non-invasive body contouring technique is designed for elective cosmetic purposes rather than weight reduction and has demonstrated moderate efficacy with predominantly mild adverse effects. The core technology was developed by Rox Anderson and his team and is licensed exclusively from Massachusetts General Hospital.
In 2009, Gordie Nye took over as CEO from Levinson, who continued to serve on the board. Initially, Zeltiq marketed its device for skin numbing before dermatological treatments and received FDA clearance through the de novo pathway in 2010. Although not originally authorized for fat removal, off-label use for body sculpting began gaining popularity.
Zeltiq’s commercial strategy combined selling CoolSculpting machines with charging clinics per treatment performed. By late 2010, the company had raised $75 million across four funding rounds. The FDA granted clearance for fat reduction on the flanks in 2010 and on the abdomen in 2012, alongside approvals from Health Canada and the European Union. By 2011, CoolSculpting was available in 46 countries spanning Europe, Asia, and North America.
The procedure’s popularity surged in the U.S. around 2011, resulting in a fourfold revenue increase to $31.6 million during the first half of that year despite ongoing operating losses. Later that year, Zeltiq’s IPO generated $91 million. By early 2012, more than 150,000 treatments had been completed worldwide.
In 2014, Zeltiq launched an upgraded version of CoolSculpting that removed the suction cup feature and secured FDA clearance to treat thighs. At this point, Zeltiq dominated the cryolipolysis market segment.
Allergan acquired Zeltiq in February 2017 for $2.48 billion to strengthen its position within the rapidly expanding body contouring sector. By mid-2020, CoolSculpting had received FDA approval for multiple treatment regions including abdomen, flanks (love handles), upper arms, back fat, bra fat, banana roll, submental area, and thighs.
This acquisition and subsequent product development reinforced Zeltiq’s market leadership and competitive edge within the aesthetic medical device industry under Allergan and later AbbVie’s global management.
CoolSculpting side effects
Linda Evangelista publicly disclosed a rare adverse reaction to CoolSculpting known as paradoxical adipose hyperplasia, which affects fewer than 1% of patients and results in an increase rather than a decrease of fatty tissue thickness. Other research indicates that side effects might be more prevalent on a per-patient basis due to multiple treatment sessions.
The EMA classifies side effects occurring in at least 1% of cases as "common," while those under 0.1% fall into "rare" or "very rare" categories. This classification framework is important when evaluating procedure risks amid its market growth and regulatory oversight.